Skip to main content

Table 2 Clinicopathologic correlations of PD-L1 expression, PIK3CA mutation, and MSI/dMMR status

From: Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma

   PD-L1 expression P PIK3CA P MSI/dMMR P
Total Positive Negative   MT WT   Positive Negative  
N = 64 (%) n = 23 (35.9%) n = 41 (64.1%)   n = 8 (12.5%) n = 56 (87.5%)   n = 11 (17.2%) n = 53 (82.8%)  
Sex     0.545    0.019    1.000
 Male 60 (93.8) 21 (91.3) 39 (95.1)   6 (75.0) 54 (96.4)   11 (100) 49 (92.5)  
 Female 4 (6.2) 2 (8.7) 2 (4.9)   2 (25.0) 2 (3.6)   0 (0.0) 4 (7.5)  
Age (years)     0.291    0.043    0.039
  ≤ 60 26 (40.6) 7 (30.4) 19 (46.3)   6 (75.0) 20 (35.7)   8 (72.7) 18 (34.0)  
  > 60 38 (59.4) 16 (69.6) 22 (53.7)   2 (25.0) 36 (64.3)   3 (27.3) 35 (66.0)  
Smoking     0.048    0.850    0.322
 Light 34 (53.1) 16 (69.6) 18 (4.9)   4 (50.0) 30 (53.6)   4 (36.4) 30 (56.6)  
 Heavy 30 (46.9) 7 (30.4) 23 (56.1)   4 (50.0) 26 (46.4)   7 (63.6) 23 (43.4)  
Alcohol     0.728    0.564    0.176
 Light 26 (40.6) 10 (43.5) 16 (39.0)   4 (50.0) 22 (39.3)   2 (18.2) 24 (45.3)  
 Heavy 38 (59.4) 13 (56.5) 25 (61.0)   4 (50.0) 34 (60.7)   9 (81.8) 29 (54.7)  
Location     0.216    0.179    1.000
 Upper/Middle 45 (70.3) 14 (60.9) 31 (48.4)   4 (50.0) 41 (73.2)   8 (72.7) 37 (69.8)  
 Lower 19 (29.7) 9 (39.1) 10 (15.6)   4 (50.0) 15 (26.8)   3 (27.3) 16 (30.2)  
Differentiation     0.291    0.253    0.039
 WD 26 (40.6) 7 (30.4) 19 (46.3)   5 (62.5) 21 (37.5)   8 (72.7) 18 (34.0)  
 MD/PD 38 (59.4) 16 (69.6) 22 (53.7)   3 (37.5) 35 (62.5)   3 (27.3) 35 (66.0)  
T category     0.622    0.282    0.428
 T1-T2 36 (56.2) 12 (52.2) 24 (58.5)   3 (37.5) 33 (58.9)   5 (45.5) 31 (58.5)  
 T3-T4 28 (43.8) 11 (47.8) 17 (41.5)   5 (62.5) 23 (41.1)   6 (54.5) 22 (41.5)  
N category     0.282    0.498    0.247
 N0 39 (60.9) 12 (52.2) 27 (65.9)   4 (50.0) 35 (62.5)   5 (45.5) 34 (64.2)  
 N1–3 25 (39.1) 11 (47.8) 14 (34.1)   4 (50.0) 21 (37.5)   6 (54.5) 19 (35.8)  
AJCC stage     0.459    0.435    0.199
 I-II 40 (62.5) 13 (56.5) 27 (65.9)   4 (50.0) 36 (64.3)   5 (45.5) 35 (66.0)  
 III-IV 24 (37.5) 10 (43.5) 14 (34.1)   4 (50.0) 20 (35.7)   6 (54.5) 18 (34.0)  
LI     0.291    0.456    1.000
 Absent 26 (40.6) 7 (30.4) 19 (46.3)   2 (25.0) 24 (42.9)   4 (36.4) 22 (41.5)  
 Present 38 (59.4) 16 (69.6) 22 (53.7)   6 (75.0) 32 (57.1)   7 (63.6) 31 (58.5)  
VI     0.648    0.683    1.000
 Absent 44 (68.8) 15 (65.2) 29 (70.7)   5 (62.5) 39 (69.6)   8 (72.7) 36 (67.9)  
 Present 20 (31.2) 8 (34.8) 12 (29.3)   3 (37.5) 17 (30.4)   3 (27.3) 17 (32.1)  
PI     0.755    0.196    1.000
 Absent 51 (79.7) 19 (82.6) 32 (78.0)   5 (62.5) 46 (82.1)   9 (81.8) 42 (79.2)  
 Present 13 (20.3) 4 (17.4) 9 (22.0)   3 (37.5) 10 (17.9)   2 (18.2) 11 (20.8)  
Skip lesion     0.345    0.673    0.431
 Absent 50 (78.1) 20 (87.0) 30 (73.2)   7 (87.5) 43 (76.8)   10 (90.9) 40 (75.5)  
 Present 14 (21.9) 3 (13.0) 11 (26.8)   1 (12.5) 13 (23.2)   1 (0.1) 13 (24.5)  
Dysplasia     0.610    0.060    0.058
 Absent 36 (56.2) 14 (60.9) 22 (53.7)   7 (87.5) 29 (51.8)   9 (81.8) 27 (50.9)  
 Present 28 (43.8) 9 (39.1) 19 (46.3)   1 (12.5) 27 (48.2)   2 (18.2) 26 (49.1)  
TIL density     0.170    0.320    0.395
 Low 22 (34.4) 5 (21.7) 17 (41.5)   4 (50.0) 18 (32.1)   5 (45.5) 17 (32.1)  
 High 42 (65.6) 18 (78.3) 24 (58.5)   4 (50.0) 38 (67.9)   6 (54.5) 36 (67.9)  
HPV     1.000    1.000    1.000
 Negative 63 (98.4) 23 (100) 40 (97.6)   8 (100) 55 (98.2)   11 (100) 52 (98.1)  
 Positive 1 (1.6) 0 (0.0) 1 (2.4)   0 (0.0) 1 (1.8)   0 (0.0) 1 (1.9)  
MSI/MMR     0.732    0.531   
 MSS/pMMR 53 (82.8) 20 (87.0) 33 (80.5)   6 (75.0) 47 (83.9)   
 MSI/dMMR 11 (17.2) 3 (13.0) 8 (19.5)   2 (25.0) 9 (16.1)   
PIK3CA status     0.700       
 Wildtype 56 (87.5) 21 (91.3) 35 (85.4)    
 Mutated 8 (12.5) 2 (8.7) 6 (14.6)    
  1. ESCC esophageal squamous cell carcinoma, PD-L1 programmed death ligand-1, MT mutated, WT wild type, MSI microsatellite instability, pMMR patent mismatch repair, dMMR deficient mismatch repair, AJCC Amedican Joint Committee on Cancer 8th edition, WD well-differentiation, MD moderately-differentiation, PD poorly-differentiation, LI lymphatic invasion, VI vascular invasion, PI perineural invasion, TIL tumor-infiltrating lymphocyte, HPV human papillomavirus